AdJane Reports First Clinical Validation of its OMV Vaccine Platform Inducing Mucosal Immunity in Humans

Contributed by: GlobeNewswire

Tags

Vaccine

More Like This

AdJane Reports First Clinical Validation of its OMV Vaccine Platform Inducing Mucosal Immunity in Humans

AdJane Unveils Mucosal Booster Strategy for Next-Generation Respiratory Vaccine Franchises

GlobeNewswire associated0

Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention

Intravacc announces positive data of first in human intranasal OMV based vaccine for SARS-CoV-2

CARB-X awards funding to AdJane to advance its nOMV platform-derived vaccine for the prevention of gonorrhea

GlobeNewswire associated0

CARB-X awards funding to AdJane to advance its nOMV platform-derived vaccine for the prevention of gonorrhea

Virometix Announces Completion of Enrollment in Phase I Trial of V-212 — a Fully Synthetic, Serotype-Independent Vaccine Candidate Against Streptococcus Pneumoniae

Virometix AG Announces Positive Data from Phase 1 Trial of V-212, a Fully Synthetic, Serotype-Independent Vaccine Development Candidate for the Prevention of Pneumococcal Disease